Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroto Matsui

Showing results (101-110 of 111) with videos related to

Pageof 12
Sort By:
Oncology Reports|March 3, 2018
IgG response to MHC class I epitope peptides is a quantitative predictive biomarker in the early course of treatment of colorectal cancer using therapeutic peptidesShinsuke Kanekiyo, Shoichi Hazama, Hiroko Takenouchi, et al.
Cancer Science|August 26, 2016
Calreticulin is highly expressed in pancreatic cancer stem-like cellsSatoshi Matsukuma, Kiyoshi Yoshimura, Tomio Ueno, et al.
JCI Insight|January 11, 2021
Islet cell dedifferentiation is a pathologic mechanism of long-standing progression of type 2 diabetesKikuko Amo-Shiinoki, Katsuya Tanabe, Yoshinobu Hoshii, et al.
International Journal of Clinical Oncology|April 12, 2020
Serum LOX-1 is a novel prognostic biomarker of colorectal cancerChiyo Nakashima-Nakasuga, Shoichi Hazama, Nobuaki Suzuki, et al.
Annals of Surgical Oncology|May 24, 2023
IL-6 Levels Correlate with Prognosis and Immunosuppressive Stromal Cells in Patients with Colorectal CancerTsunenori Yamamoto, Ryouichi Tsunedomi, Masao Nakajima, et al.
Cancer Immunology, Immunotherapy : CII|March 29, 2020
A phase I study of multi-HLA-binding peptides derived from heat shock protein 70/glypican-3 and a novel combination adjuvant of hLAG-3Ig and Poly-ICLC for patients with metastatic gastrointestinal cancers: YNP01 trialMasao Nakajima, Shoichi Hazama, Koji Tamada, et al.
Anticancer Research|July 31, 2014
Predictive biomarkers for the outcome of vaccination of five therapeutic epitope peptides for colorectal cancerShoichi Hazama, Hiroko Takenouchi, Ryouichi Tsunedomi, et al.
Medicine|June 11, 2021
A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapyYuya Hirasawa, Kiyoshi Yoshimura, Hiroto Matsui, et al.
Oncology Letters|November 26, 2020
Siglec-7 is a predictive biomarker for the efficacy of cancer vaccination against metastatic colorectal cancerKensuke Yamada, Shoichi Hazama, Nobuaki Suzuki, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 1, 2017
Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancerYoshitaro Shindo, Shoichi Hazama, Nobuaki Suzuki, et al.
Pageof 12

Showing results (101-110 of 111) with videos related to

Sort By:
Pageof 12
Oncology Reports|March 3, 2018
IgG response to MHC class I epitope peptides is a quantitative predictive biomarker in the early course of treatment of colorectal cancer using therapeutic peptidesShinsuke Kanekiyo, Shoichi Hazama, Hiroko Takenouchi, et al.
Cancer Science|August 26, 2016
Calreticulin is highly expressed in pancreatic cancer stem-like cellsSatoshi Matsukuma, Kiyoshi Yoshimura, Tomio Ueno, et al.
JCI Insight|January 11, 2021
Islet cell dedifferentiation is a pathologic mechanism of long-standing progression of type 2 diabetesKikuko Amo-Shiinoki, Katsuya Tanabe, Yoshinobu Hoshii, et al.
International Journal of Clinical Oncology|April 12, 2020
Serum LOX-1 is a novel prognostic biomarker of colorectal cancerChiyo Nakashima-Nakasuga, Shoichi Hazama, Nobuaki Suzuki, et al.
Annals of Surgical Oncology|May 24, 2023
IL-6 Levels Correlate with Prognosis and Immunosuppressive Stromal Cells in Patients with Colorectal CancerTsunenori Yamamoto, Ryouichi Tsunedomi, Masao Nakajima, et al.
Cancer Immunology, Immunotherapy : CII|March 29, 2020
A phase I study of multi-HLA-binding peptides derived from heat shock protein 70/glypican-3 and a novel combination adjuvant of hLAG-3Ig and Poly-ICLC for patients with metastatic gastrointestinal cancers: YNP01 trialMasao Nakajima, Shoichi Hazama, Koji Tamada, et al.
Anticancer Research|July 31, 2014
Predictive biomarkers for the outcome of vaccination of five therapeutic epitope peptides for colorectal cancerShoichi Hazama, Hiroko Takenouchi, Ryouichi Tsunedomi, et al.
Medicine|June 11, 2021
A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapyYuya Hirasawa, Kiyoshi Yoshimura, Hiroto Matsui, et al.
Oncology Letters|November 26, 2020
Siglec-7 is a predictive biomarker for the efficacy of cancer vaccination against metastatic colorectal cancerKensuke Yamada, Shoichi Hazama, Nobuaki Suzuki, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 1, 2017
Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancerYoshitaro Shindo, Shoichi Hazama, Nobuaki Suzuki, et al.
Pageof 12